drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous TCR-T)
drug_description
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-A1 peptide presented by HLA-A*01:01; targets peptide–HLA on tumor cells to induce TCR/CD3-mediated cytotoxic killing after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Transgenic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A1 peptide presented by HLA-A*01:01. After lymphodepletion, these TCR-T cells recognize the peptide–HLA complex on tumor cells, activate TCR/CD3 signaling, and mediate targeted cytotoxic killing.
drug_name
TSC-204-A0101
nct_id_drug_ref
NCT05973487